Why ivonescimab data at ELCC 2026 matters for Summit Therapeutics (SMMT)

Summit Therapeutics (SMMT) drew investor attention after presenting new clinical data for its investigational bispecific antibody, ivonescimab, at the 2026 European Lung Cancer Congress in Copenhagen.

The update covered multiple Phase III trials in non small cell lung cancer and colorectal cancer, providing new information on the progress of Summit’s late stage pipeline and how that progress may relate to the current share price.

Ivonescimab’s ELCC 2026 showing comes at a time when Summit Therapeutics’ share price has moved to $19.38, with a 7 day share price return of 16.89%, a 30 day share price return of 28.26% and a 1 year total shareholder return of 11.64%. The 3 year total shareholder return is very large, suggesting momentum has been building over a longer horizon.

If you are looking beyond a single biotech story, this is a useful moment to broaden your watchlist and check out 36 healthcare AI stocks

With Summit now valued at about US$15.0b and the share price at US$19.38, recent gains and a large multi year return raise a key question: is there still upside here, or is the market already pricing in future growth?

Most Popular Narrative: 33.6% Undervalued

At a last close of $19.38 versus a narrative fair value of $29.18, the current price sits well below what the most followed model implies.

The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.

Want to understand why a company with no current revenue still commands this valuation gap? The core of the narrative leans on steep revenue ramps, margin expansion from today’s losses toward industry norms, and a rich future earnings multiple that assumes those shifts hold. Curious which assumptions move the model most and how sensitive the fair value is to small changes in those inputs? The full story joins those pieces together.

Result: Fair Value of $29.18 (UNDERVALUED)

However, this hinges on a single lead asset, and setbacks in key HARMONi trials or prolonged cash burn without product revenue could quickly challenge that upbeat narrative.

Next Steps

If this mix of optimism and concern feels familiar, that is the point. The market is split, and you should weigh the trade off yourself using 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If ivonescimab has your attention, do not stop there. Broaden your opportunity set with a few focused stock lists built to surface different types of potential.

• Spot potential value candidates early by scanning companies trading on attractive terms with the 58 high quality undervalued stocks
• Build a shortlist of cash generative businesses by checking the solid balance sheet and fundamentals stocks screener (40 results)
• Get ahead of the crowd by reviewing the screener containing 25 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.